Back to Search
Start Over
Improving Chemotherapy Effectiveness: Utilizing CuS Nanoparticles Coated with AS1411 Aptamer and Chitosan for Targeted Delivery of Doxorubicin to Cancerous Cells.
- Source :
-
Journal of pharmaceutical sciences [J Pharm Sci] 2024 Jul; Vol. 113 (7), pp. 1865-1873. Date of Electronic Publication: 2024 Feb 10. - Publication Year :
- 2024
-
Abstract
- Here, a novel targeted nanostructure complex was designed as an alternative to the traditional treatment approaches for breast cancer. A delivery system utilizing CuS nanoparticles (CuS NPs) was developed for the purpose of targeted administration of doxorubicin (Dox), an anticancer agent. To regulate Dox release, chitosan (CS), a biodegradable and hydrophilic polymer with biocompatible properties, was applied to coat the Dox-loaded CuS NPs. Furthermore, AS1411 aptamer, served as a targeting agent for breast cancer cells (MCF-7 and 4T1 cells), was conjugated with CS-Dox-CuS NPs effectively. To assess the effectiveness of APT-CS-CuS NPs, various methods such as flow cytometry analysis, MTT assay, fluorescence imaging, and in vivo antitumor efficacy were employed. The hollow core and porous surface of CuS NPs improved the Dox loading capacity and entrapment efficiency (almost 100%). The rate of drug release at the tumor site (citrate buffer with pH 5.6) exhibited a marked increase in comparison to that observed within the physiological environment (phosphate buffer with pH 7.4). The targeted formulation (APT-CS-Dox-CuS NPs) significantly increased cytotoxicity of the Dox payload in target cells, including 4T1 (p ≤ 0.0001 (****)) and MCF7 (p ≤ 0.01 (**)) cells compared to CHO cells. Moreover, the ability of tumor growth inhibition of the targeted system was significantly (p ≤ 0.05 (*)) more than free Dox in tumor-bearing mice. The findings indicate that the targeted formulation augmented effectiveness and specificity while minimizing harm to non-targeted cells, signifying its potential as a sophisticated cancer drug delivery system.<br />Competing Interests: Declaration of competing interest There is no conflict of interest about this article.<br /> (Copyright © 2024 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Animals
Humans
Female
Mice
MCF-7 Cells
Cell Line, Tumor
Antibiotics, Antineoplastic administration & dosage
Antibiotics, Antineoplastic pharmacokinetics
Antibiotics, Antineoplastic pharmacology
Antibiotics, Antineoplastic chemistry
Breast Neoplasms drug therapy
Breast Neoplasms pathology
Drug Delivery Systems methods
Mice, Inbred BALB C
Drug Liberation
Drug Carriers chemistry
Cricetulus
CHO Cells
Copper
Oligodeoxyribonucleotides
Doxorubicin administration & dosage
Doxorubicin pharmacology
Doxorubicin pharmacokinetics
Doxorubicin chemistry
Chitosan chemistry
Aptamers, Nucleotide chemistry
Aptamers, Nucleotide administration & dosage
Nanoparticles chemistry
Subjects
Details
- Language :
- English
- ISSN :
- 1520-6017
- Volume :
- 113
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Journal of pharmaceutical sciences
- Publication Type :
- Academic Journal
- Accession number :
- 38342338
- Full Text :
- https://doi.org/10.1016/j.xphs.2024.02.005